HsT16795: Key Regulator of DNA Replication and Cell Signaling

Target Name: RPL21P14

NCBI ID: G729208

RPL21P14

Other Name(s): HsT16795 | Ribosomal protein L21 pseudogene 14 | RPL21_53_1436 | ribosomal protein L21 pseudogene 14

HsT16795: Key Regulator of DNA Replication and Cell Signaling

RPL21P14 (HsT16795) is a protein that is expressed in various tissues of the human body, including the brain, heart, and liver. It is a key regulator of the Replication-Capture complex (RCC), a critical protein that ensures the efficient replication of DNA in eukaryotic cells. The RCC plays a vital role in the regulation of DNA replication, repair, and quality control. HsT16795 is a member of the P160 family of proteins, which are known to be involved in various cellular processes, including cell signaling, DNA replication, and cell survival.

The protein encoded by HsT16795 is composed of 1,942 amino acid residues and has a calculated molecular weight of 21 kDa. It consists of a unique N-terminus, a catalytic core, and a C-terminus. The N-terminus of HsT16795 is rich in various domains, including a nucleotide-binding oligomerization domain (NBO), a zinc finger domain, and a putative transmembrane domain (TMD). The NBO is a common protein domain that is known to be involved in various cellular processes, including DNA replication, transcription, and signaling. The zinc finger domain is a conserved protein domain that is known to be involved in various cellular processes, including protein-protein interactions, DNA replication, and repair. The TMD is a transmembrane domain that is involved in the regulation of protein trafficking and localization.

HsT16795 is a protein that has been shown to play a critical role in the regulation of DNA replication in various cell types. For example, HsT16795 has been shown to be involved in the regulation of DNA replication in T cells, a type of white blood cell that plays a vital role in the immune system. In T cells, HsT16795 is expressed at high levels and is involved in the regulation of DNA replication, repair, and quality control.

Another study has shown that HsT16795 is involved in the regulation of DNA replication in cancer cells. For example, HsT16795 has been shown to be involved in the regulation of DNA replication in breast cancer cells, a type of cancer that is one of the most common types of cancer in women. In breast cancer cells, HsT16795 is expressed at high levels and is involved in the regulation of DNA replication, repair, and quality control.

In addition to its role in DNA replication, HsT16795 has also been shown to play a critical role in the regulation of cell signaling. For example, HsT16795 has been shown to be involved in the regulation of theNotch signaling pathway, a signaling pathway that is involved in various cellular processes, including cell growth, differentiation, and survival.

Furthermore, HsT16795 has also been shown to be involved in the regulation of protein-protein interactions. For example, HsT16795 has been shown to be involved in the regulation of the interaction between the protein tyrosine kinase (TK) and its ligand, tyrosine. This interaction is critical for the regulation of various cellular processes, including cell signaling, DNA replication, and repair.

In conclusion, HsT16795 is a protein that is involved in various cellular processes, including cell signaling, DNA replication, and repair. Its unique N-terminus, catalytic core, and C-terminus have been shown to play a critical role in the regulation of DNA replication in various cell types. Further research is needed to fully understand the role of HsT16795 in

Protein Name: Ribosomal Protein L21 Pseudogene 14

The "RPL21P14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL21P14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets